Rewriting the rules for care of MDS and AML patients in the time of COVID-19 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Rewriting the rules for care of MDS and AML patients in the time of COVID-19

  1. Home
  2. Education
  3. Research Articles
Journal Title: 
Leukemia Research Reports
Primary Author: 
Raza A
Author(s): 
Raza A, Assal A, Ali AM, Jurcic JG
Original Publication Date: 
Monday, April 20, 2020
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/32318330/
Bone Marrow Disease(s): 

The care of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) has been radically altered by COVID-19, especially in New York City, the epicenter of the pandemic. Here we summarize how telemedicine, virtual visits, delayed transfusions, and chemotherapy, preferably selecting self-administered medications and visits by home healthcare workers, are employed to minimize exposure of our high-risk population of patients to the virus. The unique challenges of transplants during the pandemic and the consequences of an abrupt halt in all non-essential research activities are described. Not all the changes forced by COVID-19 are detrimental.